Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion
NASDAQ:IMA

ImageneBio Q4 2024 Earnings Report

ImageneBio logo
$5.56 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$5.64 +0.08 (+1.35%)
As of 05/22/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

ImageneBio EPS Results

Actual EPS
-$2.16
Consensus EPS
-$2.76
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Announcement Details

Quarter
Q4 2024
Date
3/11/2025
Time
Before Market Opens
Conference Call Date
Wednesday, March 5, 2025
Conference Call Time
6:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

ImageneBio's Q4 2024 Annual reportAnnual report
(10-K)

ImageneBio Earnings Headlines

ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to Strong Sell
May 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30782478
ImageneBio (IMA) price target decreased by 18.75% to 13.26
May 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/imagenebio-ima-price-target-decreased-by-1875-to-1326/ar-AA239i1S
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
May 25 at 1:00 AM  |  Weiss Ratings (Ad)
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290583/0/en/imagenebio-reports-first-quarter-2026-financial-results-and-provides-img-007-program-update.html
ImageneBio Inc.
April 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/ima/company-people
IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally?
April 13, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ima-stock-surges-24-breaks-50-dma-for-first-time-since-february-whats-driving-the-rally/ar-AA20Ns5C
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA), a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

View ImageneBio Profile
Earnings Tools